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COMPARING THE COST-EFFECTIVENESS OF 3
MCG/KG Q2W DARBEPOETIN ALFA WITH
STANDARD DOSE EPOETIN ALFA FOR ANEMIA
MANAGEMENT IN CHEMOTHERAPY-TREATED
CANCER PATIENTS IN UNITED STATES
Glaspy J1,Tchekmedyian N2, Gupta S3
1University of California-Los Angeles, Los Angeles, CA, USA;
2Paciﬁc Shores Medical Group, Long Beach, CA, USA;
3Amgen, Inc,Thousand Oaks, CA, USA
OBJECTIVES: A recent 12-week phase 2 randomized
clinical trial evaluated the hemoglobin (hgb) response
rates (% patients with hgb increase ≥2g/dL from base-
line, in the absence of RBC transfusion) of four different
dosing schedules of darbepoetin alfa administered every
other week (q2w) to anemic patients with solid tumors
receiving chemotherapy. A randomized group of epoetin
alfa patients (40,000U/wk; dose escalated to 
60,000U/wk at 6 weeks for inadequate response) was the
active control. Recent literature indicates the mean dura-
tion of anemia treatment with epoetin alfa for cancer
patients on chemotherapy to be 16 to 24 weeks. We
designed a 20-week model to evaluate the cost-
effectiveness of 3.0mcg/kg Q2wk of darbepoetin alfa (n
= 33) compared to epo (n = 32). METHODS: Average
wholesale prices (AWPs) of the 2 drugs in United States
were used as the sole cost driver over the expected 20-
week anemia treatment period. Response rates at week
12 were used as the efﬁcacy measures for the two thera-
pies. RESULTS: Mean cumulative 20-week doses per
patient for darbepoetin alfa and epoetin alfa were esti-
mated to be 2,100mcg (assuming mean patient weight =
70kg) and 844,800U, respectively. Compared to the esti-
mated 20-week cost of epoetin alfa therapy, darbepoetin
alfa was estimated to be $800 less per patient (For the
12-week trial duration, darbpoetin alfa was about $380
cheaper). The response rates at the end of week 12 were
found to be similar (60%, with similar conﬁdence inter-
vals) for the 2 therapies. Smaller percent patients (3%
versus 7%) required RBC transfusions in darbepoetin alfa
group. Cost-effectiveness ratio (cost per % patients with
hgb response) was superior for darbepoetin alfa ($17,465
versus $18,812). CONCLUSIONS: Compared to stan-
dard practice epoetin alfa therapy, 3.0mcg/kg Q2wk dar-
bepoetin alfa provides a less expensive and cost-effective
alternative to treat cancer patients with chemotherapy-
induced anemia.
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DERIVING A UTILITY WEIGHTED INDEX FROM
CONDITION-SPECIFIC MEASURES: PRACTICAL
SOLUTIONS FOR ECONOMIC EVALUTIONS
Kind P1, Uyl-de groot CA2, Buigt I2, Macran S1
1University of York,York, United Kingdom; 2Erasmus University,
Rotterdam, Netherlands
Clinical trial health outcome data intended for the pur-
poses of economic evaluation must be capable of being
represented by a single, summary index. When beneﬁts
are to be estimated in terms of quality-adjusted life 
years that index needs to represent social preference
weights/utilities. However clinical trials often fail to
include utility-weighted measures in their protocols.
OBJECTIVE: To describe the strategic options available
to the researchers’ facing the task of deriving a utility
weighted index from a condition speciﬁc measure, using
the FACT-L as a case study. METHODS: The FACT-L 
is a widely used instrument that deﬁnes health-related
quality of life in terms of four dimensions: physical,
social, emotional and functional well-being. As far as 
is known, utility weights for the items/levels within the
FACT-L have not so far been published. The complexity
of the FACT-L makes it impossible to estimate utility
weights using traditional MAUT methods. Hence the sim-
pliﬁcation of the descriptive system is an essential pre-
requisite. Two separate strategies do this were adopted,
based ﬁrstly on the analysis of pre-existing responses on
the FACT-L, obtained in a clinical study of 431 patients
with non-small cell lung cancer and secondly on the
results of ﬁve qualitative interviews with oncologists
experienced in the use of FACT-L were performed.
RESULTS: The factor analytic approach yield limited
scope for item reduction although a more efﬁcient clus-
tering of items within dimensions was achieved. The qual-
itative review produced greater scope for simpliﬁcation 
of the descriptive system. CONCLUSIONS: An efﬁcient
subset of FACT-L items that have clinical descriptive
salience can be achieved as a preliminary to the estima-
tion of item/level utility weights.
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EXAMINING PREFERENCES AND TIME-
TRADE-OFF UTILITY FOR GEMCITABINE PLUS
CISPLATIN IN THE TREATMENT OF BLADDER
CANCER:A SURVEY USING DISCRETE CHOICE
CONJOINT ANALYSIS IN THE UK
Brown A1, Aristides M1, FitzGerald P2, Davey P2, Bhalla S3,
Kielhorn A3
1M-TAG Limited, London, United Kingdom; 2M-TAG Pty Ltd,
Sydney, Australia; 3Eli Lilly and Company Limited, Windlesham,
Surrey, United Kingdom
OBJECTIVES: The National Institute for Clinical Excel-
lence in the UK encourage provision of health-related
quality of life (QoL) evidence for their assessments and
recently their guidance has ﬂagged the importance of
patient preference in therapy selection. Gemcitabine 
plus cisplatin (GC) displays comparable efﬁcacy to the
methotrexate, vinblastine, doxorubicin plus cisplatin
(MVAC) regimen in treating advanced bladder cancer but
shows signiﬁcant advantage in terms of tolerability and
serious adverse events. Therefore a UK study was con-
ducted to examine patient value associated with the tox-
icity proﬁle of GC, compared with MVAC. METHODS:
A novel application of discrete choice conjoint analysis
was employed to quantify preference and time-trade-off
utility differences providing sensitive strength of prefer-
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ence measures and utility values for individual treat-
ment attributes. Differential toxicity attributes, that were
patient relevant and clinically signiﬁcant, were identiﬁed
from head-to-head trial data. Attributes identiﬁed were:
alopecia, weight loss, mucositis, diarrhoea, and febrile
neutropenia/neutropenic sepsis. Fourteen oncologists and
16 oncology nurses served as patient proxies given the
sensitive nature and ethical difﬁculties associated with the
patient population. Respondents considered an orthogo-
nally designed series of pair-wise choice scenarios repre-
senting incidence levels for individual toxicity attributes
(treatment features) with trade-offs in life-expectancy. 
A logistic regression was utilised to analyse the stated 
scenario pair preferences against the individual attribute
levels. Potential confounders were analysed. RESULTS:
Survey results indicate a strong preference for GC treat-
ment and a clear willingness-to-trade-time for tolerability
beneﬁts. Analysis of strength of preference for individual
attributes shows strong support for treatment features
that impact directly on QoL. CONCLUSIONS: UK
respondents displayed a clear preference for GC treat-
ment with superior toxicity offering a highly valued
health related QoL gain. These results provide encour-
agement for further exploration, possibly by extension to
the European setting. Discrete choice conjoint analysis is
a promising instrument in the outcomes assessment of
cancer therapies.
CANCER—Clinical Outcomes
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IS THERE DIFFERENCE BETWEEN
GEMCITABINE BASED NSCLC TREATMENT AND
OTHER PLATINUM BASED COMBINATIONS FOR
RESPONSE RATES AND TOXICITY?
Bhalla S, Kielhorn A, Maniadakis N
Eli Lilly, Windlesham, Surrey, United Kingdom
OBJECTIVE: This analysis attempts to highlight the 
differences in response rates and toxicity between 
Gemcitabine combined with a platinum-based therapy
and other combinations of platinum-based chemother-
apy, in the treatment of non-small-cell lung cancer
(NSCLC). METHODS: This pooled analysis used
summary statistics from clinical trials published up to
December 2001. The analysis pooled odds ratios (OR)
and associated conﬁdence intervals (CI) using a ﬁxed-
effects model. The efﬁcacy outcomes considered are
responses (both partial and complete) and progressive
disease. Grade 3 and 4 toxicities are considered using the
WHO criteria for the following adverse events: alopecia,
nausea and vomiting, anaemia, neutropenia, thrombocy-
topenia and neuropathy. RESULTS: Patients receiving
Gemcitabine combined with a platinum therapy are more
likely to experience a response to treatment than patients
receiving other platinum based combinations. The OR for
complete and partial responses is 2.68, (CI 1.53–4.67)
and is 0.44 for progressive disease (CI 0.32–0.59). Gem-
citabine patients experienced fewer cases of alopecia 
(OR 0.15, CI 0.10–0.22) and neutropenia (OR 0.6, CI
0.47–0.77). In contrast, Gemcitabine patients experi-
enced a greater number of grade 3 or 4 anaemia (OR
1.92, CI 1.41–2.61) and thrombocytopenia (OR 6.76 CI
4.95–9.23) incidences. For neuropathy and nausea and
vomiting there was no evidence for any of the chemother-
apies having fewer patients experiencing toxicities. CON-
CLUSIONS: The implications of this analysis at the
patient level is that if response is of primary importance,
then on a purely clinical basis Gemcitabine should be the
treatment of choice. Gemzar based chemotherapy had a
higher number of responses and fewer adverse events 
for alopecia and neutropenia. To validate these results, a
meta-analysis should be conducted with stratiﬁcation for
key variables using patient level data.
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CANCER CHEMOTHERAPY AT HOME:
FEASIBILITY, PATIENT OUTCOMES,AND
HEALTHCARE SYSTEM IMPLICATIONS
Boothroyd LJ1, Lehoux P2
1Agence d’Evaluation des Technologies et des Modes
d’Intervention en Sante, Montreal, QC, Canada; 2University of
Montreal, Montreal, QC, Canada
OBJECTIVES: At the Quebec Health Technology Assess-
ment Agency (AETMIS) in Canada we assessed whether
home chemotherapy for cancer was effective, safe, and
satisfactory to patients, and examined the cost, organi-
zational, and ethical implications, in order to make 
policy recommendations. METHODS: We carried out 
a systematic review of the scientiﬁc literature using 
the PubMed (MEDLINE 1980–present) and CancerLit
(1975–present) bibliographic databases. We supple-
mented this review with 16 semi-structured interviews
with service providers, including oncology nurses, physi-
cians, and home care coordinators, in 2 provinces 
with different organizational structures for cancer care
(Quebec and Ontario). RESULTS: Clinical effectiveness
of home cancer chemotherapy appears similar to that 
in non-home settings. Home treatment can be delivered
safely if patients are carefully selected and trained. Patient
eligibility criteria relate to learning capability, suitability
of the home environment, and geographic accessibility.
Improvements in patient quality of life at home have not
been well documented in the literature. Patient preference
and satisfaction with home therapy is supported,
although mostly among self-selected groups. Cost studies
show that home chemotherapy is less expensive than
inpatient treatment from a hospital perspective. When
home treatment is used as a substitute for outpatient
therapy, the result tends to be a cost shifting from hospi-
tals to home care organizations. Effects on costs to
patients/families require more study. Interviews with
service providers showed variable delivery, with greater
patient load capacity and uniformity of services where
hospital oncology departments or regionalized centres 
